Efanesoctocog alpha

Efanesoctocog alpha is a factor a replacement therapy designed to decouple recombinant factor VIII from endogenous Willebrand’s factor and overcome  the VWF imposed half life ceiling.

Efanesoctocog alpha in severe hemophilia A provided once weekly had superior bleeding prevention to pre-study prophylaxis, normal to near normal factor VIII activity and improvements in physical health, pain, and joint health.

Efanesoctocog alpha is composed of a single recombinant factor VIII protein and three additional components that contribute to its increased half-life.


Leave a Reply

Your email address will not be published. Required fields are marked *